Injective price analysis: INJ targets 17 dollars amid rising interest

Injective is currently showing signs of a strong recovery as the asset gains traction among traders and long term holders alike. Market data indicates that the token is pushing toward a key resistance level at 17 dollars. This upward movement is supported by a noticeable increase in open interest, which suggests that traders are building positions in anticipation of further gains. When open interest rises alongside price, it often signals that new capital is entering the market to support the current trend.

Staking activity has also played a major role in the recent price action. More participants are locking their tokens into the network, which effectively reduces the circulating supply available on exchanges. This supply squeeze can accelerate price appreciation when demand remains steady or increases. Investors appear to be prioritizing yield generation through native staking as they wait for the broader market to confirm a sustainable trend for the remainder of 2026.

Technical indicators suggest that if the current momentum holds, the 17 dollar level is a realistic target. Traders are watching the volume patterns closely to see if the buying pressure is sufficient to break past previous short term ceilings. If Injective manages to clear this hurdle, it could set the stage for a move toward higher price discovery levels that have not been tested for several months.

However, market participants should remain cautious as volatility is typical for assets experiencing rapid interest growth. While the sentiment is currently bullish, the broader crypto market performance will likely influence whether Injective can maintain its pace. Traders are monitoring the funding rates across major derivatives platforms to ensure the current rally is not overextended or reliant on excessive leverage.

Overall, the combination of increased staking and growing derivatives volume provides a solid foundation for the current price move. As we progress through the middle of 2026, the focus will remain on whether the support levels hold during potential profit taking periods. If the current trend persists, Injective may continue to attract institutional interest, which could provide the necessary backing for a long term breakout above the psychological 17 dollar barrier.